Tumor-activated prodrugs - A new approach to cancer therapy

Cancer Investigation

Volumn 22, Issue 4, 2004, Pages 604-619

  Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Activated prodrugs; Cancer therapy; Tumor

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; 5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ALKYLATING AGENT; AMIDASE; AMIDE; AROMATIC NITRO COMPOUND; CYCLOPHOSPHAMIDE; CYTOSINE DEAMINASE; DOXORUBICIN; DOXORUBICIN DERIVATIVE; DUOCARMYCIN A; FLUCYTOSINE; GANCICLOVIR; GEMTUZUMAB OZOGAMICIN; GLYCOSIDASE; HEPTAPEPTIDE; L 377202; MONOCLONAL ANTIBODY; NUCLEOSIDE DERIVATIVE; OXIDE; PHOSPHATASE; PHOSPHOTRANSFERASE; PRODRUG; QUINONE DERIVATIVE; RACHELMYCIN; SB 408075; TIAZOFURIN; TIRAPAZAMINE; TUMOR ACTIVATED PRODRUG; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BYSTANDER EFFECT; CANCER THERAPY; CELL KILLING; CLINICAL TRIAL; DRUG ACTIVATION; HUMAN; HYDROLYSIS; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANOXIA; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; GENES, TRANSGENIC, SUICIDE; HUMANS; IMMUNOTOXINS; NEOPLASMS; PRODRUGS; RADIOTHERAPY;

EID: 8644280287     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-200027148     Document Type: Review

References (90)

1. Frei, E.; Teicher, B.A.; Holden, S.A.; Cathcart, K.N.; Wang, Y.Y. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res. 1998, 48, 6417-6423.
2. Denny, W.A.; Wilson, W.R.; Hay, M.P. Recent developments in the design of bioreductive drugs. Br. J. Cancer 1996, 74 (Supp. 27), 32-38.
3. Wilson, W.R.; Pullen, S.M.; Hogg, A.; Helsby, N.A.; Hicks, K.O.; Denny, W.A. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res. 2002, 62, 1425-1432.
4. Denny, W.A. Prodrug strategies in cancer therapy. Eur. J. Med. Chem. 2001, 36, 577-595.
5. Denny, W.A.; Wilson, W.R. Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Met. Rev. 1993, 12, 135-151.
6. Weber, G.; Prajda, N.; Abonyi, M.; Look, K.Y.; Tricot, G. Tiazofurin: molecular and clinical action. Anticancer Res. 1996, 16, 3313-3322.
7. Bailey, S.M.; Wyatt, M.D.; Friedlos, F.; Hartley, J.A.; Knox, R.J.; Lewis, A.D.; Workman, P. Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA crosslinking and sequence selectivity of the bioreductive antitumor agent EO9. Br. J. Cancer 1997, 76, 1596-1603.
8. Fitzsimmons, S.A.; Workman, P.; Grever, M.; Paull, K.; Camalier, R.; Lewis, A.D. Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J. Natl. Cancer Inst. 1996, 88, 259-269.
9. Pavlidis, N.; Hanauske, A.R.; Gamucci, T.; Smyth, J.; Lehnert, M.; Te Velde, A.; Lan, J.; Verweij, J. A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG). Ann. Oncol. 1996, 7, 529-531.
10. Dirix, L.Y.; Tonnesen, F.; Cassidy, J.; Epelbaum, R.; ten Bokkel Huinink, W.W.; Pavlidis, N.; Sorio, R.; Gamucci, T.; Wolff, I.; Te Velde, A.; Lan, J.; Verweij, J. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group. Eur. J. Cancer 1996, 32A, 2019-2022.
11. Cummings, J.; Spanswick, V.J.; Gardiner, J.; Ritchie, A.; Smyth, J.F. Pharmacological and biochemical determinants of the antitumor activity of the indoloquinone EO9. Biochem. Pharmacol. 1998, 55, 253-260.
12. McLeod, H.L.; Graham, M.A.; Aamdal, S.; Setanoians, A.; Groot, Y.; Lund, B. Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug E09. Eur. J. Cancer 1996, 32A, 1518-1522.
13. Breistol, K.; Hendriks, H.R.; Berger, D.P.; Langdon, S.P.; Fiebig, H.H.; Fodstad, O. The antitumor activity of the prodrug N-L-leucyldoxorubicin and its parent compound doxorubicin in human tumor xenografts. Eur. J. Cancer 1998, 34, 1602-1606.
14. DeFeo-Jones, D.; Garsky, V.M.; Wong, B.K.; Feng, D.M.; Bolyar, T.; Haskell, K.; Kiefer, D.M.; Leander, K.; McAvoy, E.; Lumma, P.; Wai, J.; Senderak, E.T.; Motzel, S.L.; Van Zwieten, K.M.; Lin, J.H.; Freidinger, R.; Huff, J.; Oliff, A.; Jones, R.E. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat. Med. 2000, 6, 1248-1252.
15. Wong, B.K.; DeFeo-Jones, D.; Jones, R.E.; Garsky, V.M.; Feng, D.M.; Oliff, A.; Chiba, M.; Ellis, J.D.; Lin, J.H. PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites. Drug Met. Disp. 2001, 29, 313-318.
16. DiPaola, R.S.; Rinehart, J.; Nemunaitis, J.; Ebbinghaus, S.; Rubin, E.; Capanna, T.; Ciardella, M.; Doyle-Lindrud, S.; Goodwin, S.; Fontaine, M.; Adams, N.; Williams, A.; Schwartz, M.; Winchell, G.; Wickersham, K.; Deutsch, P.; Yao, S.-L. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J. Clin. Oncol. 2002, 20, 1874-1879.
17. Dubowchik, G.M.; Walker, M.A. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharm. Ther. 1999, 83, 67-123.
18. Sjogren, H.O.; Isaksson, M.; Willner, D.; Hellstrom, I.; Hellstrom, K.E.; Trail, P.A. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Res. 1997, 57, 4530-4536.
19. Saleh, M.N.; Sugarman, S.; Murray, J.; Ostroff, J.B.; Healey, D.; Jones, D.; Daniel, C.R.; LeBherz, D.; Brewer, H.; Onetto, N.; LoBuglio, A.F. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J. Clin. Oncol. 2000, 18, 2282-2292.
20. Hinman, L.M.; Hamann, P.R.; Wallace, R.; Menendez, A.T.; Durr, F.E.; Upeslacis, J. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. 1993, 53, 3336-3342.
21. Knoll, K.; Wrasidlo, W.; Scherberich, J.E.; Gaedicke, G.; Fischer, P. Targeted therapy of experimental renal cell carcinoma with a novel conjugate of monoclonal antibody 138H11 and calicheamicin γII. Cancer Res. 2000, 60, 6089-6094.
22. Siegel, M.M.; Tabei, K.; Kunz, A.; Hollander, I.J.; Hamann, P.R.; Bell, D.H.; Berkenkamp, S.; Hillenkamp, F. Calicheamicin derivatives conjugated to monoclonal antibodies: determination of loading values and distributions by infrared and UV matrix-assisted laser desorption/ionization mass spectrometry and electrospray ionization mass spectrometry. Anal. Chem. 1997, 69, 2716-2726.
23. Larson, R.A.; Boogaerts, M.; Estey, E.; Karanes, C.; Stadtmauer, E.A.; Sievers, E.L.; Mineur, P.; Bennett, J.M.; Berger, M.S.; Eten, C.B.; Munteanu, M.; Loken, M.R.; van Dongen, J.J.M.; Bernstein, I.D.; Appelbaum, F.R. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002, 16, 1627-1636.
24. Liu, C.; Chari, R.V.J. The development of antibody delivery systems to target cancer with highly potent maytansinoids. Expert Opin. Investig. Drugs 1997, 6, 169-172.
25. Liu, C.; Tadayoni, B.M.; Bourret, L.A.; Mattocks, K.M.; Derr, S.M.; Widdison, W.C.; Kedersha, N.L.; Ariniello, P.D.; Goldmacher, V.; Lambert, J.M.; Blattler, W.A.; Chari, R.V. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 8618-8623.
26. Boger, D.L.; Johnson, D.S. CC-1065 and the duocarmycins-understanding their biological function through mechanistic studies. Angew. Chem., Int. Ed. 1996, 35, 1438-1474.
27. Suzawa, T.; Nagamura, S.; Saito, H.; Ohta, S.; Hanai, N.; Yamasaki, M. Synthesis of a novel duocarmycin derivative DU-257 and its application to immunoconjugate using poly(ethylene glycol)-dipeptidyl linker capable of tumor specific activation. Bioorg. Med. Chem. 2000, 8, 2175-2184.
28. Deonarain, M.P.; Epenetos, A.A. Targeting enzymes for cancer therapy: old enzymes in new roles. Br. J. Cancer 1994, 70, 786-794.
29. Niculescu-Duvaz, L; Friedlos, F.; Niculescu-Duvaz, D.; Davies, L.; Springer, C.J. Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT). Anti-Cancer Drug Des. 1999, 14, 517-538.
30. Bagshawe, K.D.; Sharma, S.K.; Springer, C.J.; Rogers, G. Antibody directed enzyme prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects. Anal. Oncol. 1994, 5, 879-891.
31. Blakey, D.C.; Burke, P.J.; Davies, D.H.; Dowell, R.I.; East, S.J.; Ekersley, K.P.; Fitton, J.E.; McDaid, J.; Melton, R.J.; Niculescu-Duvas, I.; Pinder, P.E.; Sharma, S.K.; Wright, A.F.; Springer, C.J. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts. Cancer Res. 1996, 56, 3287-3292.
32. Monks, N.R.; Calvete, J.A.; Curtin, N.J.; Blakey, D.C.; East, S.J.; Newell, D.R. Cellular glutathione as a determinant of the sensitivity of colorectal tumor cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT). Br. J. Cancer 2000, 83, 267-269.
33. Kerr, D.E.; Schreiber, G.J.; Vrudhula, V.M.; Svensson, H.P.; Hellstrom, I.; Hellstrom, K.E.; Senter, P.D. Regressions and cures of melanoma xenografts following treatment with monoclonal antibody β-lactamase conjugates in combination with anticancer prodrugs. Cancer Res. 1995, 55, 3558-3563.
34. Meyer, D.L.; Jungheim, L.N.; Mikolajczyk, S.D.; Starling, J.J.; Alhem, C.N. Preparation and characterization of a β-lactamase-Fab′ conjugate for the site-specific activation of oncolytic agents. Bioconjug. Chem. 1992, 3, 42-48.
35. Meyer, D.L.; Jungheim, L.N.; Law, K.L.; Mikolajczyk, S.D.; Shepherd, T.A.; Makensen, D.G.; Briggs, S.L.; Starling, J.J. Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models. Cancer Res. 1993, 53, 3956-3963.
36. Svensson, H.P.; Vrudhula, V.M.; Emswiler, J.E.; MacMaster, J.F.; Cosand, W.L.; Senter, P.D.; Wallace, P.M. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody β-lactamase conjugates. Cancer Res. 1995, 55, 2357-2365.
37. Wang, S.M.; Chern, J.W.; Yeh, M.Y.; Ng, J.C.; Tung, E.; Roffler, S.R. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Cancer Res. 1992, 52, 4484-4491.
38. Houba, P.H.J.; Boven, E.; Van Der Meulen-Muileman, I.H.; Leenders, R.G.G.; Scheeren, J.W.; Pinedo, H.M.; Haisma, H.J. A novel doxorubicin- glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. Int. J. Cancer 2001, 91, 550-554.
39. Greco, O.; Dachs, G.U. Gene directed enzyme/ prodrug therapy of cancer: historical appraisal and future prospectives. J. Cell. Physiol. 2001, 187, 22-36.
40. Wildner, O. In situ use of suicide genes for therapy of brain tumours. Ann. Med. 1999, 31, 421-429.
41. Ishii-Morita, H.; Agbaria, R.; Mullen, C.A.; Hirano, H.; Koeplin, D.A.; Ram, Z.; Oldfield, E.H.; Johns, D.G.; Blaese, R.M. Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther. 1997, 4, 244-251.
42. Mesnil, M.; Yamasaki, H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res. 2000, 60, 3989-3999.
43. Rainov, N.G.; Fetell, M.; Cloughesy, T.; et al. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 2000, 11, 2389-2401.
44. Denny, W.A. Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). J. Biomed. Biotech. 2003, 3, 49-70.
45. Kievit, E.; Bershad, E.; Ng, E.; Sethna, P.; Dev, I.; Lawrence, T.S.; Rehemtulla, A. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res. 1999, 59, 1417-1421.
46. Huber, B.; Austin, E.; Richards, C.; Davis, S.; Good, S. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 8302-8306.
47. Pandha, H.S.; Martin, L.; Rigg, A.; Hurst, H.C.; Stamp, G.W.H.; Sikora, K.; Lemoine, N.R. Prodrug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression. J. Clin. Oncol. 1999, 17, 2180-2189.
48. Leichman, C.G. Schedule dependency of 5-fluorouracil. Oncology 1999, 13, 26-32.
49. Waxman, D.J.; Chen, L.; Hecht, J.E.; Jounaidi, Y. Cytochrome P450-based cancer gene therapy: recent advances and future prospects. Drug Met. Rev. 1999, 31, 503-522.
50. Wei, M.X.; Tamiya, T.; Rhee, R.J.; Breakefield, X.O.; Chiocca, E.A. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin. Cancer Res. 1995, 1, 1171-1177.
51. Hunt, S. Technology evaluation: MetXia-P450, Oxford BioMedica. Curr. Opin. Mol. Ther. 2001, 3, 595-598.
52. Lohr, M.; Bago, Z.T.; Bergmeister, H.; et al. Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intraarterially in patients with advanced-stage pancreatic carcinoma: a phase I/II study. J. Mol. Med. 1999, 77, 393-398.
53. Lohr, M.; Hummel, F.; Faulmann, G.; Ringel, J.; Sailer, R.; Hain, J.; Gunzburg, W.H.; Salmons, B. Microencapsulated, CYP2B1-transfected cells activating ifosfamide at the site of the tumor: the magic bullets of the 21st century. Cancer Chemother. Pharmacol. 2002, 49 (Suppl. 1), S21-S24.
54. Anlezark, G.M.; Melton, R.G.; Sherwood, R.F.; Coles, B.; Friedlos, F.; Knox, R.J. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954). I. Purification and properties of a nitroreductase enzyme from Escherichia coil. A potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. 1992, 44, 2289-2295.
55. Knox, R.J.; Friedlos, F.; Marchbank, T.; Roberts, J.J. Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand cross-linking species. Biochem. Pharmacol. 1991, 42, 1691-1697.
56. Palmer, D.H.; Mautner, V.; Mirza, D.; Buckels, J.; Olliff, D.; Hull, D.; Mountain, A.; Harris, P.; Djeha, H.; Ellis, J.; Horne, M.; Hill, S.; Wrighton, C.; Searle, P.P.; Kerr, D.J.; Young, L.S.; James, N.D. Virus-directed enzyme prodrug therapy (VDEPT): clinical trials with adenoviral nitroimidazole reductase (Ad-ntr). Br. J. Cancer 2002, S6(Suppl. 1), S30.
57. Chung-Faye, G.; Palmer, D.; Anderson, D.; Clark, J.; Downes, M.; Baddeley, J.; Hussain, S.; Murray, P.I.; Searle, P.; Seymour, L.; Harris, P.A.; Ferry, D.; Kerr, D.J. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin. Cancer Res. 2001, 7, 2662-2668.
58. Anlezark, G.M.; Melton, R.G.; Sherwood, R.F.; Wilson, W.R.; Denny, W.A.; Palmer, B.D.; Knox, R.J.; Friedlos, F.; Williams, A. Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem. Pharmacol. 1995, 50, 609-615.
59. Harris, A.L. Hypoxia-a key regulatory factor in tumor growth. Nat. Rev. Cancer 2002, 2, 38-47.
60. Baish, J.W.; Netti, P.A.; Jain, R.K. Transmural coupling of fluid flow in microcirculatory network and interstitium in tumors. Microvasc. Res. 1997, 53, 128-141.
61. Movsas, B.; Chapman, J.D.; Horwitz, E.M.; Pinover, W.H.; Greenberg, R.E.; Hanion, A.L.; Iyer, R.; Hanks, G.E. Hypoxic regions exist in human prostate carcinoma. Urology 1999, 53, 11-18.
62. Patterson, A.V.; Saunders, M.P.; Chinje, E.G.; Patterson, LH.; Stratford, I.J. Enzymology of tirapazamine metabolism: a review. Anti-Cancer Drug Des. 1998, 13, 541-573.
63. Brown, J.M. The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1999, 59, 5863-5870.
64. Hwang, J.T.; Greenberg, M.M.; Fuchs, T.; Gates, K.S. Reaction of the hypoxia-selective antitumor agent tirapazamine with a Cl′-radical in single-stranded and double-stranded DNA: the drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions. Biochemistry 1999, 38, 14248-14255.
65. Lartigau, E.; Guichard, M. Does tirapazamine (SR-4233) have any cytotoxic or sensitizing effect on three human tumour cell lines at clinically relevant partial oxygen pressure? Int. J. Radiat. Biol. 1995, 67, 211-216.
66. Senan, S.; Rampling, R.; Graham, M.A.; Wilson, P.; Robin, H.; Eckardt, N.; Lawson, N.; McDonald, A.; von Roemeling, R.; Workman, P.; Kaye, S.B. Phase I and pharmacokinetic study of tirapazamine (SR-4233) administered every three weeks. Clin. Cancer Res. 1997, 3, 31-38.
67. Lee, D.J.; Trotti, A.; Spencer, S.; Rostock, R.; Fisher, C.; von Roemeling, R.; Harvey, E.; Groves, E. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a phase II study. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42, 811-815.
68. Kovacs, M.S.; Hocking, D.J.; Evans, J.W.; Slim, B.G.; Wouters, B.G.; Brown, J.M. Cisplatin antitumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br. J. Cancer 1999, 80, 1245-1251.
69. Von Pawel, J.; Von Roemeling, R.; Gatzemeier, U.; Boyer, M.; Elisson, L.O.; Clark, P.; Talbot, D.; Rey, A.; Butler, T.W.; Hirsh, V.; Olver, I.; Bergman, B.; Ayoub, J.; Richardson, G.; Dunlop, D.; Arcenas, A.; Vescio, R.; Viallet, J.; Treat, J. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. J. Clin. Oncol. 2000, 18, 1351-1359.
70. Miller, V.A.; Ng, K.K.; Grant, S.C.; Kindler, H.; Pizzo, B.; Heelan, R.T.; von Roemeling, R.; Kris, M.G. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol. 1997, 8, 1269-1271.
71. Lee, A.E.; Wilson, W.R. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol. Appl. Pharmacol. 2000, 163, 50-59.
72. Raleigh, S.M.; Wanogho, E.; Burke, M.D.; McKeown, S.R.; Patterson, L.H. Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42, 763-767.
73. Smith, P.J.; Blunt, N.J.; Desnoyers, R.; Giles, Y.; Patterson, L.H. DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides. Cancer Chemother. Pharmacol. 1997, 39, 455-461.
74. Patterson, L.H.; McKeown, S.R.; Ruparelia, K.; Double, J.A.; Bibby, M.C.; Cole, S.; Stratford, I.J. Enhancement of chemotherapy and radiotherapy of murine tumors by AQ4N, a bioreductively activated anti-tumor agent. Br. J. Cancer 2000, 82, 1984-1990.
75. Friery, O.P.; Gallagher, R.; Murray, M.M.; Hughes, C.M.; Galligan, E.S.; McIntyre, I.A.; Patterson, L.H.; Hirst, D.G.; McKeown, S.R. Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine. Br. J. Cancer 2000, 82, 1469-1473.
76. Patterson, L.H. Bioreductively activated antitumor N-oxides: the case of AO4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug Met. Rev. 2002, 34, 581-592.
77. Belcourt, M.F.; Hodnick, W.F.; Rockwell, S.; Sartorelli, A.C. Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 456-460.
78. Belcourt, M.F.; Hodnick, W.F.; Rockwell, S.; Sartorelli, A.C. Exploring the mechanistic aspects of mitomycin antibiotic bioactivation in Chinese hamster ovary cells overexpressing NADPH:cytochrome C (P-450) reductase and DT-diaphorase. Adv. Enzyme Regul. 1998, 38, 111-133.
79. Tomasz, M.; Palom, Y. The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity. Pharmacol. Ther. 1997, 76, 73-87.
80. Haffty, B.G.; Son, Y.H.; Wilson, L.D.; Papac, R.; Fischer, D.; Rockwell, S.; Sartorelli, A.C.; Ross, D.; Sasaki, C.T.; Fischer, J.J. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck. Radiat. Oncol. Investig. 1997, 5, 235-245.
81. Beall, H.D.; Winski, S.L. Mechanisms of action of quinone-containing alkylating agents. I. NQOI-directed drug development. Front. Biosci. 2000, 5, D639-D648.
82. Chung-Faye, G.; Palmer, C.; Anderson, D.; Clark, J.; Downes, M.; Baddeley, J.; Hussain, S.; Murray, P.I.; Searle, P.; Seymour, L.; Harris, P.A.; Ferry, D.; Kerr, D.J. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin. Cancer Res. 2001, 7, 2662-2668.
83. Breider, M.A.; Pilcher, G.D.; Graziano, M.J.; Gough, A.W. Retinal degeneration in rats induced by CI-1010, a 2-nitroimidazole radiosensitizer. Toxicol. Pathol. 1998, 26, 234-239.
84. Wilson, W.R.; Tercel, M.; Anderson, R.F.; Denny, W.A. Reduction of nitroarylmethyl quaternary ammonium prodrugs of mechlorethamine by radiation. Anti-Cancer Drug Des. 1998, 13, 663-685.
85. Wilson, W.R.; Denny, W.A.; Tercel, M. Radiation-Activated Cytotoxins: A New Use for Roentgen's Rays in Cancer Treatment; Hagen, U., Harder, D., Jung, H., Streffer, C., Eds.; Proc. 10th Int. Congr. Radiat. Res., 1996; Vol. 2, 791-794.
86. Mori, M.; Hatta, H.; Nishimoto, S.J. Stereoelectronic effect on one-electron reductive release of 5-fluorouracil from 5-fluoro-1-(2′- oxocycloalkyl)uracils as a new class of radiation-activated antitumor prodrugs. Org. Chem. 2000, 65, 4641-4647.
87. Shibamoto, Y.; Zhou, L.; Hatta, H.; Mori, M.; Nishimoto, S.-I. A novel class of antitumor prodrug, 1-(2′-Oxopropyl)-5-fluorouracil (OFU001), that releases 5-fluorouracil upon hypoxic irradiation. Jpn. J. Cancer Res. 2000, 91, 433-438.
88. Shibamoto, Y.; Zhou, L.; Hatta, H.; Mori, M.; Nishmoto, S. In vivo evaluation of a novel antitumor prodrug, 1-(2′-oxopropyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation. Int. J. Radiat. Oncol. Biol. Phys. 2001, 49, 407-413.
89. Wilson, W.R.; Ferry, D.M.; Tercel, M.; Anderson, R.F.; Denny, W.A. Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts. Radiat. Res. 1998, 149, 237-245.
90. Denny, W.A.; Wilson, W.R.; Ware, D.C.; Atwell, G.J.; Milbank, J.B.J.; Stevenson, R.J. Anticancer 8-Substituted Quinolines and 2,3-Dihydro-1H- Pyrrolo[3,2-f]Quinoline Complexes of Cobalt and Chromium; PCT Int. Appl. WO 0259122 A1, Auckland Uniservices Limited: NZ, August 1, 2002; 97 pp.